Search

Displaying results 1401 - 1410 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-13:0/a-17:0)[rac]

    smpdb.ca/view/SMP0371347
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-15:0/a-15:0)[rac]

    smpdb.ca/view/SMP0371364
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-17:0/a-17:0)[rac]

    smpdb.ca/view/SMP0371383
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-21:0/a-13:0)[rac]

    smpdb.ca/view/SMP0371400
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-25:0/a-15:0)[rac]

    smpdb.ca/view/SMP0371419
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  6. Pathway

    Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-25:0/a-17:0)[rac]

    smpdb.ca/view/SMP0371420
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Target

    Cyclin-A2

    go.drugbank.com/bio_entities/BE0003734
    TargetHumans

    Essential for the control of the cell cycle at G1/S and G2/M transition (PubMed:1312467). Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or ...

    Synonyms: Cyclin A, Cyclin-A
  8. Target

    Hemocyanin 1

    go.drugbank.com/bio_entities/BE0010299
    TargetMegathura crenulata

    Hemocyanins are copper-containing oxygen carriers occurring freely dissolved in the hemolymph of many mollusks and arthropods.

    Synonyms: KLH-A, Keyhole limpet hemocyanin A
  9. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetine
  10. Pathway

    Monoamine Oxidase-A Deficiency (MAO-A)

    smpdb.ca/view/SMP0125595
    Disease

    Momoamine oxidase A (MAO-A) deficiency, or Brunner syndrome, is an X-linked recessive genetic disorder caused by a mutation in the MAOA gene that encodes for monoamine oxidase A. … With the inactivation of MAO-A, 3-methoxytyramine builds up as there are no reactions that use it, and both of these paths lead to a decrease in the concentration of homovanillic acid, as there are no

    Drugs: Pyridoxal phosphate · Ademetionine · Ascorbic acid · Aspartic acid · Tyrosine · Glutamic acid +20 more
    Enzymes: Amine oxidase [flavin-containing] A, Amiloride-sensitive amine oxidase [copper-containing]